Lipoprotein(a): The Cardiovascular Risk Factor Your Doctor May Be Missing

At a Glance

Cardiovascular disease remains the leading cause of death globally, and yet one of the most powerful risk factors — lipoprotein(a) — is absent from nearly every routine lipid panel. Patients with high Lp(a) may have LDL levels in the “optimal” range, pass a standard cardiovascular workup, and still be silently accumulating atherosclerotic plaque and aortic valve calcification at a rate that vastly exceeds their apparent risk profile.

In my practice, we now test Lp(a) as a baseline cardiovascular screening tool for all patients, not just those with established heart disease. The test costs roughly the same as a TSH, takes one blood draw, and changes clinical management in approximately one of every five patients.

This article explains what Lp(a) is, why conventional medicine underdiagnoses it, how to interpret your numbers, and what you can actually do if yours is elevated.

What Is Lp(a) and Why Does It Matter?

Lipoprotein(a) is a modified form of LDL. Its core structure is a standard LDL particle — a cholesterol-rich ball surrounded by apolipoprotein B-100 — with an additional protein, apolipoprotein(a) [written “Lpa” to distinguish it from the particle “Lp(a)”], linked to it by a single disulfide bond. That extra protein is what makes Lp(a) uniquely dangerous.

Apo(a) structurally resembles plasminogen, the precursor to plasmin (the enzyme that dissolves blood clots). Because of this molecular mimicry, Lp(a):

1. Competes with plasminogen for binding sites on fibrin, impairing clot breakdown and promoting a prothrombotic state
2. Preferentially deposits in arterial walls, where it oxidizes and triggers local inflammation more aggressively than standard LDL
3. Accumulates in aortic valve leaflets, accelerating calcific aortic stenosis — a completely distinct mechanism from atherosclerosis

This triple threat explains why Lp(a)‘s cardiovascular effect is not simply additive to LDL risk: high Lp(a) promotes plaque formation, makes existing plaques more prone to rupture, and impairs the body’s ability to dissolve the resulting clots.

The Genetic Architecture

The LPA gene on chromosome 6 is highly polymorphic. The most important variable is the number of “kringle IV type 2” (KIV-2) repeats in the apo(a) protein: more repeats = larger apo(a) = lower Lp(a) concentration. Paradoxically, the smaller isoforms (fewer KIV-2 repeats) produce less apo(a) protein individually but circulate in higher concentration and appear more atherogenic.

Because of this Mendelian genetics, Lp(a) levels are about 90% heritable, making family history the best screening prompt. A parent or sibling with premature coronary artery disease, aortic stenosis, or stroke is an indication to test their first-degree relatives regardless of conventional lipid results.

Who Should Be Tested — and When

Current guidelines recommend at least one lifetime Lp(a) measurement for all adults. In practice, I extend this to:

• All patients, at baseline — one measurement is usually sufficient since Lp(a) is largely genetic and stable across adulthood
• Premature ASCVD (men < 55, women < 65) with no obvious traditional risk factors
• Family history of premature heart disease, aortic stenosis, stroke, or clotting disorders
• Intermediate or borderline cardiovascular risk where the 10-year pooled cohort risk score leaves management decisions uncertain
• Before starting hormone therapy — exogenous estrogen (oral) significantly elevates Lp(a) in some individuals; transdermal estrogen appears neutral
• Statin non-responders — when LDL is controlled but residual cardiovascular events continue
• Recurrent ASCVD or unexplained aortic valve disease in patients already optimized on standard lipid therapy

One measurement is generally adequate because levels are stable over time. Re-testing is warranted only when a major hormonal change occurs (menopause, HRT initiation, significant weight loss) or when a new high-potency lipid-lowering drug is started.

How to Test and Interpret Results

Ordering the Test

Lp(a) is not included in a standard lipid panel. You must order it explicitly — listed on laboratory requisitions as “Lipoprotein(a)” or “Lp(a).” It requires a single fasting or non-fasting blood draw; Lp(a) does not require fasting, though drawing it alongside a full lipid panel (which may require fasting) is practical.

Units: The Critical Confusion

Labs report Lp(a) in either mg/dL (mass) or nmol/L (molar concentration), and these are not interchangeable at a fixed ratio because the mass per particle varies with apo(a) isoform size. As a rule of thumb:

• mg/dL × 2.5 ≈ nmol/L (approximation; isoform-corrected assays give the true molar value)
• nmol/L is the preferred unit in research — mass-based assays can underestimate risk in patients with large isoforms

When comparing serial measurements or values across labs, confirm the unit and the assay type.

Reference Ranges

The European Heart Journal and ESC Dyslipidaemia Guidelines (2019) use ≥ 50 mg/dL (≥ 125 nmol/L) as the threshold for “high-risk” Lp(a). The U.S. NLHBI uses a similar cut-off. However, some cardiologists treat any level > 30 mg/dL as actionable when accompanied by other cardiovascular risk factors.

What Lowers Lp(a)?

This is the section patients most want answered — and the honest answer is that the options, while expanding rapidly, are still limited compared to the toolkit for LDL.

What Does NOT Appreciably Lower Lp(a)

• Statins: Statins upregulate LDL receptors, which clear LDL but only minimally affect Lp(a); some data suggest statins may actually modestly increase Lp(a) by 10–15%, possibly by reducing hepatic LDL-R-mediated clearance of apo(a)
• Ezetimibe: Minimal effect
• Dietary change alone: Low-fat diets produce only modest reductions (< 15%)
• Exercise: Cardiorespiratory fitness modestly lowers Lp(a) by 10–15% in sedentary individuals but does not normalize highly elevated levels
• Most supplements: Berberine, omega-3, plant sterols, niacin (in lower doses) — minimal to no impact

Established Interventions

PCSK9 inhibitors (evolocumab, alirocumab) are the only widely available drugs with meaningful Lp(a) reduction: approximately 20–25% decrease in Lp(a) alongside their primary LDL-lowering effect. For patients with both high LDL and high Lp(a), PCSK9 inhibitors address both simultaneously. The FOURIER trial demonstrated that evolocumab’s cardiovascular benefit was disproportionately larger in patients with high baseline Lp(a).

Inclisiran (siRNA targeting PCSK9) produces similar Lp(a) reductions to PCSK9 inhibitor antibodies — approximately 20% — with twice-yearly dosing.

High-dose niacin (1,500–3,000 mg/day extended-release) can lower Lp(a) by 20–30%. However, niacin’s overall cardiovascular benefit in trials (AIM-HIGH, HPS2-THRIVE) was disappointing, and niacin is rarely used now given side effect burden and limited outcomes benefit.

Lp(a)-apheresis: In Germany and select EU countries (and for some patients in the US through special access), weekly or biweekly LDL apheresis specifically targeting Lp(a) remains the only intervention that reliably reduces Lp(a) by 60–80% per session. It is reserved for patients with very high Lp(a) and progressive ASCVD despite maximal medical therapy. The procedure is similar to plasmapheresis — blood is processed through adsorption columns that selectively remove apo(B)-containing particles.

Emerging RNA-Based Therapies (2025–2026)

The most exciting developments are RNA interference (RNAi) and antisense oligonucleotide (ASO) therapies targeting the LPA gene directly:

Olpasiran (Amgen) — RNAi, subcutaneous, quarterly dosing. Phase 3 trials (OCEAN) demonstrated 80–90% Lp(a) reductions. FDA decision expected 2026.

Zerlasiran (Silence Therapeutics) — RNAi, similar reduction profile to olpasiran.

Pelacarsen (Novartis) — ASO, monthly subcutaneous, approximately 75–80% Lp(a) reduction. The HORIZON cardiovascular outcomes trial is ongoing.

Muvalaplin (AstraZeneca/Ionis) — an oral small molecule that disrupts the apo(a)/apoB linkage. Phase 2 data showed 65–85% Lp(a) reduction. A purely oral option would transform access.

These agents do not yet have broad regulatory approval, but the clinical reality is that highly elevated Lp(a) (> 200 nmol/L) with progression of atherosclerosis or aortic stenosis represents a compelling use case for compassionate access or trial enrollment.

Clinical Management: A Practical Framework

When I receive an elevated Lp(a) result, my approach is structured around risk stratification rather than the number in isolation.

Step 1 — Confirm the absolute risk context. A 35-year-old with Lp(a) of 80 mg/dL and no other risk factors faces a different clinical problem than a 58-year-old with the same Lp(a), hypertension, metabolic syndrome, and a family history of MI at 50. Risk calculators (pooled cohort equations) notoriously underestimate risk in high-Lp(a) individuals; I often apply a manual upward adjustment.

Step 2 — Optimize all modifiable factors aggressively. Since Lp(a) itself is difficult to lower, the surrounding risk factors must be tighter than standard targets. LDL < 50 mg/dL (not < 100), blood pressure in the low-normal range, hs-CRP < 1 mg/L, optimal glycaemia, no smoking, high cardiorespiratory fitness. Think of high Lp(a) as dramatically lowering your “threshold” — the same LDL of 100 mg/dL that’s acceptable in a low-Lp(a) person is unacceptable in a high-Lp(a) patient.

Step 3 — Consider coronary imaging. A coronary artery calcium (CAC) score in patients with elevated Lp(a) is extremely useful for reclassifying risk and motivating treatment. A CAC of 0 in a 45-year-old with high Lp(a) is somewhat reassuring; a CAC of 400 at the same age demands immediate, intensive intervention.

Step 4 — PCSK9 inhibitor as pharmacological anchor. For high-Lp(a) patients already on a statin, I discuss adding a PCSK9 inhibitor when 10-year ASCVD risk exceeds 7.5% or when there is established ASCVD. The ~20% Lp(a) reduction is meaningful even if it does not normalize high levels — it reduces the atherogenic particle burden.

Step 5 — Aspirin consideration. The prothrombotic mechanism of Lp(a) has led some guidelines to extend low-dose aspirin (81 mg daily) to high-Lp(a) patients with intermediate cardiovascular risk who would not otherwise qualify. The individualized risk-benefit calculation must weigh bleeding risk, particularly in patients already on antifibrinolytic agents or anticoagulants.

Lifestyle and Nutritional Levers

While no supplement lowers Lp(a) dramatically, several nutritional strategies reduce overall atherogenic burden and are warranted regardless:

Omega-3 fatty acids (EPA+DHA, 2–4 g/day): Do not lower Lp(a) but reduce triglycerides, lower VLDL, and reduce residual inflammatory risk (icosapent ethyl/Vascepa in REDUCE-IT).

Lipoprotein-friendly diet: Reducing saturated fat intake (replace with monounsaturated and polyunsaturated fats) lowers LDL and provides some marginal benefit for Lp(a). The Mediterranean dietary pattern remains the best-evidenced dietary approach.

Vitamin C and Lp(a): Linus Pauling’s hypothesis that vitamin C deficiency drives Lp(a) elevation as a “surrogate repair mechanism” remains controversial but has generated interest. Some observational data suggest high-dose vitamin C (2–4 g/day) modestly reduces Lp(a). The evidence does not yet support this as a primary intervention but is harmless to include in a broader antioxidant protocol.

Reducing lipoprotein-oxidizing exposures: Minimizing oxidized LDL through a low-inflammatory lifestyle (no smoking, anti-inflammatory diet, adequate CoQ10 and tocotrienols) reduces the downstream damage of circulating Lp(a) even when the level itself does not change.

Related Articles

• ApoB vs LDL: Which Cardiovascular Marker Actually Predicts Risk?
• Functional Medicine Labs: What to Order and Why
• CoQ10 for Heart Health: Dosing, Evidence, and Statin Interactions
• PCSK9 Inhibitors and Lipid Apheresis for Complex Dyslipidemias
• Longevity Stack: A Physician’s Annual Review

References

1. Nordestgaard BG, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. PMID 20965889

2. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188. PMID 31504418

3. O’Donoghue ML, et al. Evolocumab and cardiovascular outcomes in patients with high Lp(a) — a prespecified analysis of FOURIER. Circulation. 2019;139(12):1483–1492. PMID 30605368

4. Tsimikas S, et al. Pelacarsen (TQJ230) for the treatment of elevated lipoprotein(a): HORIZON trial design. Eur J Prev Cardiol. 2023;30(8):737–744. PMID 36652369

5. Nicholls SJ, et al. Olpasiran reduces lipoprotein(a) and cardiovascular risk: the OCEAN(a)-DOSE trial. NEJM. 2022;387(21):1952–1962. PMID 36342011

6. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946. PMID 36036785

7. Yeang C, et al. Muvalaplin, an oral small molecule inhibitor of Lp(a) formation. JAMA. 2023;330(11):1042–1053. PMID 37605229